Netazepide - Trio Medicines

Drug Profile

Netazepide - Trio Medicines

Alternative Names: YF 476

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma; Trio Medicines
  • Developer Ferring Pharmaceuticals; Trio Medicines
  • Class
  • Mechanism of Action Cholecystokinin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Barrett's oesophagus
  • No development reported Gastric cancer; Gastritis
  • Discontinued Gastro-oesophageal reflux; Peptic ulcer; Reflux oesophagitis

Most Recent Events

  • 29 Jan 2018 Netazepide is still in phase II trials for Barrett's oesophagus in USA and United Kingdom (NCT01298999)
  • 15 Dec 2016 Biomarkers information updated
  • 17 Jun 2015 Phase-II clinical trials in Barrett's oesophagus in USA and United Kingdom (PO) (NCT01298999; UKCRN18198)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top